Home/Pipeline/Oncology Pipeline (pH-sensitive antibodies)

Oncology Pipeline (pH-sensitive antibodies)

Oncology

Pre-clinicalActive

Key Facts

Indication

Oncology

Phase

Pre-clinical

Status

Active

Company

Mabqi

About Mabqi

Mabqi is a Paris-based biotech founded in 2017, specializing in AI-driven antibody discovery. Its core platform, the LiteMab Antibody Discovery Studio, utilizes proprietary fully human synthetic libraries and high-throughput display technologies to generate therapeutic antibodies against challenging targets like GPCRs and ion channels. The company is building an internal oncology pipeline featuring pH-sensitive antibodies and is also positioned as a discovery partner for other biopharma entities. Mabqi operates as a private, pre-revenue company in the pre-clinical stage.

View full company profile

Therapeutic Areas

Oncology

Other Oncology Drugs

Drug	Company	Phase	Status
Bi-XDC with PROTACs	Coherent Biopharma	IND-enabling	Active
Bi-XDC with RPT	Coherent Biopharma	Early-stage	Active
mRNA Anticancer Vaccine	Sunshine Biopharma	Preclinical Research	Active
Biosimilar Bevacizumab	Organon (2)	Phase 3	Active
Biosimilar Pembrolizumab	Organon (2)	Phase 3	Active
BCL-2 Inhibitor Program	Vincerx Pharma	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Preclinical Projects	Zion Pharma	Preclinical	Active
Attenukine Oncology Candidate	Teva	Phase 1	Active
XEMA Tumor Marker ELISA Kit	XEMA Group	Commercial	Active
KRAS inhibitor	Risen Pharma Tech	Preclinical/Phase 1	Active (AACR 2024 presentation)
KEAP1 Activator Program	Vividion Therapeutics	Phase 1	Active